Ekhagastiftelsen Report issue

Academic/Hospital Phase 3

Organization Overview

First Clinical Trial
2000
NCT00894816
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2016

Timeline

NOW
  • Now

Alternative names

Ekhagastiftelsen

Active Ingredients

Drugs in Phase 3 Trials (2)

lactobacillus casei (1 trial)

mistletoe (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Dental Caries (Phase 3)

Eczema (Phase 3)

Hypersensitivity (Phase 3)

Obesity (Phase 3)

Pancreatic Neoplasms (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 2
  • # of Trial APIs: 2